Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis.
Jonathan I Silverberg, Thomas Bieber, Kilian Eyerich et al.
✦ AI-curated · Sources linked
In 30 seconds
This pooled subgroup analysis of two randomized, double-blind, placebo-controlled phase 3 trials examined serum lebrikizumab levels and sustained response after treatment withdrawal in adults and adolescents with moderate-to-severe atopic dermatitis. Among Week 16 responders re-randomized to placebo, 28% (17/60) maintained stable EASI 90 response without rescue medication through Week 52. Mean serum lebrikizumab fell from 92.4 μg/mL at Week 16 to 0.15 μg/mL at Week 52. The authors report that a subset maintained response for at least 38 weeks after discontinuation.
Key findings
- During withdrawal, 28% (17/60) maintained stable EASI 90 response without rescue medication through Week 52.
- Mean serum lebrikizumab decreased by 92% from Week 16 to Week 32 and by over 99% from Week 16 to Week 52.
- Mean serum levels were 92.4 μg/mL at Week 16, 7.3 μg/mL at Week 32, and 0.15 μg/mL at Week 52.
Why it matters
The findings indicate that some patients who respond to lebrikizumab may retain a deep clinical response for months after stopping treatment, even as circulating drug levels decline substantially. This provides useful context for understanding response durability after withdrawal, while the subgroup result does not establish how commonly this occurs across all treated patients.
What to keep in mind
The analysis was restricted to Week 16 responders re-randomized to placebo who maintained stable EASI 90 response for at least 80% of visits and used no rescue medication; its findings therefore apply to a selected subgroup.